doi	title	authors	title_name	year	downloads	visitors	countries
10.2217/pgs.15.45	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients	Raffaella Pasquale, Francesca Fenizia, Riziero Esposito Abate, Alessandra Sacco, Claudia Esposito, Laura Forgione, Anna Maria Rachiglio, Simona Bevilacqua, Agnese Montanino, Renato Franco, Gaetano Rocco, Gerardo Botti, Marc G Denis, Alessandro Morabito, Antonella De Luca, Nicola Normanno	Pharmacogenomics	2015	17	16	9
10.2217/pgs.14.127	SNPs and taxane toxicity in breast cancer patients	Virginia Bosó, María José Herrero, Ana Santaballa, Laura Palomar, Juan E Megias, Helena de la Cueva, Luis Rojas, María Remedios Marqués, José Luis Poveda, Joaquin Montalar, Salvador F Aliño	Pharmacogenomics	2014	15	15	5
10.2217/pgs.14.152	Pharmacogenomics of glinides	Miao Chen, Cheng Hu, Weiping Jia	Pharmacogenomics	2015	13	13	9
10.2217/pgs.14.172	Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients	Silvo Koder, Katja Repnik, Ivan Ferkolj, Cvetka Pernat, Pavel Skok, Rinse K Weersma, Uroš Potočnik	Pharmacogenomics	2015	14	13	8
10.2217/pgs.15.41	Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups	Yijing He, Janelle M Hoskins, Scott Clark, Nathan H Campbell, Kim Wagner, Alison A Motsinger-Reif, Howard L McLeod	Pharmacogenomics	2015	16	13	6
10.2217/pgs.15.62	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients	Mohammad Salem Hareedy, Ehab S El Desoky, Jean-Baptiste Woillard, Romany Helmy Thabet, Amany Mohamad Ali, Pierre Marquet, Nicolas Picard	Pharmacogenomics	2015	15	13	8
10.2217/pgs.15.63	Molecular biomarkers in colorectal carcinoma	Elena Puerta-García, Marisa Cañadas-Garre, Miguel Ángel Calleja-Hernández	Pharmacogenomics	2015	14	13	7
10.2217/pgs.14.106	Pharmacogenetics of childhood acute lymphoblastic leukemia	Elixabet Lopez-Lopez, Angela Gutierrez-Camino, Nerea Bilbao-Aldaiturriaga, Maria Pombar-Gomez, Idoia Martin-Guerrero, Africa Garcia-Orad	Pharmacogenomics	2014	12	12	9
10.2217/pgs.15.88	De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer	Adela Madrid-Paredes, Marisa Cañadas-Garre, Antonio Sánchez-Pozo, Miguel Ángel Calleja-Hernández	Pharmacogenomics	2015	13	12	6
10.2217/pgs.14.89	Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy	Chun-Lai Ma, Xun-Yi Wu, Jiao Zheng, Zhi-Yuan Wu, Zhen Hong, Ming-Kang Zhong	Pharmacogenomics	2014	12	11	5
10.2217/pgs.13.198	Pharmacogenomic biomarkers in drug labels: what do they tell us?	Richard Tutton	Pharmacogenomics	2014	12	10	5
10.2217/pgs.14.171	Pharmacogenomics toward personalized tamoxifen therapy for breast cancer	Hitoshi Zembutsu	Pharmacogenomics	2015	10	10	7
10.2217/pgs.15.15	Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders	Sarah G Helton, Falk W Lohoff	Pharmacogenomics	2015	10	10	5
10.2217/pgs.14.133	Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies	Inês de Paula Costa Monteiro, Pedro Madureira, Alessandro de Vasconscelos, Daniel Humberto Pozza, Ramon Andrade de Mello	Pharmacogenomics	2015	9	9	6
10.2217/pgs.14.135	HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients	Ingrid Fricke-Galindo, Iris E Martínez-Juárez, Nancy Monroy-Jaramillo, Helgi Jung-Cook, Ramcés Falfán-Valencia, Alberto Ortega-Vázquez, María Elisa Alonso-Vilatela, Marisol López-López	Pharmacogenomics	2014	8	8	6
10.2217/pgs.14.93	Parkinson's disease pharmacogenomics: new findings and perspectives	Artur F Schumacher-Schuh, Carlos RM Rieder, Mara H Hutz	Pharmacogenomics	2014	8	8	7
10.2217/pgs.15.29	Update on thiopurine pharmacogenetics in inflammatory bowel disease	Rebecca L Roberts, Murray L Barclay	Pharmacogenomics	2015	9	8	5
10.2217/pgs.15.4	Role of dermatology in pharmacogenomics: drug-induced skin injury	Riccardo G Borroni	Pharmacogenomics	2015	10	8	5
10.2217/pgs.15.58	International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events	Sefayet Karaca, Nujen Colak Bozkurt, Tomris Cesuroglu, Mehmet Karaca, Mehmet Bozkurt, Erdal Eskioglu, Renato Polimanti	Pharmacogenomics	2015	13	8	5
10.2217/pgs.15.6	Pharmacogenomics of cyclooxygenases	José AG Agúndez, Miguel Blanca, José A Cornejo-García, Elena García-Martín	Pharmacogenomics	2015	8	8	7
10.2217/pgs.13.221	Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis	Jin-A Jung, Hyeong-Seok Lim	Pharmacogenomics	2014	14	7	3
10.2217/pgs.14.124	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma	Nicola Silvestris, Bruno Vincenzi, Anna Elisabetta Brunetti, Fotious Loupakis, Emanuela Dell'Aquila, Antonio Russo, Mario Scartozzi, Riccardo Giampieri, Stefano Cascinu, Vito Lorusso, Giuseppe Tonini, Alfredo Falcone, Daniele Santini	Pharmacogenomics	2014	7	7	6
10.2217/pgs.14.170	In vitro human cell line models to predict clinical response to anticancer drugs	Nifang Niu, Liewei Wang	Pharmacogenomics	2015	7	7	5
10.2217/pgs.14.38	Future of pharmacogenetics-based therapy for tuberculosis	Tomoshige Matsumoto, Masako Ohno, Junichi Azuma	Pharmacogenomics	2014	8	7	6
10.2217/pgs.14.65	Pharmacogenetics of antiepileptic drug-induced hypersensitivity	Katarzyna M Bloch, Graeme J Sills, Munir Pirmohamed, Ana Alfirevic	Pharmacogenomics	2014	7	7	6
10.2217/pgs.15.85	Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations	John Jack, Tammy M Havener, Howard L McLeod, Alison A Motsinger-Reif, Matthew Foster	Pharmacogenomics	2015	8	7	5
10.2217/pgs.15.92	Point-of-care molecular diagnostic devices: an overview	Chi Lan Nguyen Vu, Jianxiong Chan, Marian Todaro, Stan Skafidas, Patrick Kwan	Pharmacogenomics	2015	8	7	5
10.2217/pgs.15.94	Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy	Chun-Lai Ma, Zheng Jiao, Xun-Yi Wu, Zhen Hong, Zhi-Yuan Wu, Ming-Kang Zhong	Pharmacogenomics	2015	8	7	6
10.2217/pgs.14.116	Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers	Aurea Lima, Hugo Sousa, Joaquim Monteiro, Rita Azevedo, Rui Medeiros, Vitor Seabra	Pharmacogenomics	2014	6	6	4
10.2217/pgs.14.138	 POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia 	Euridiki Drogari, Georgia Ragia, Vasiliki Mollaki, Laure Elens, Ron HN Van Schaik, Vangelis G Manolopoulos	Pharmacogenomics	2014	6	6	4
10.2217/pgs.15.20	Pharmacometabonomics in humans: a new tool for personalized medicine	Jeremy R Everett	Pharmacogenomics	2015	15	6	4
10.2217/pgs.15.90	Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis	Gwan Gyu Song, Young Ho Seo, Jae-Hoon Kim, Sung Jae Choi, Jong Dae Ji, Young Ho Lee	Pharmacogenomics	2015	7	6	4
10.2217/pgs.13.244	SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients	Aurea Lima, Miguel Bernardes, Hugo Sousa, Rita Azevedo, Lúcia Costa, Francisco Ventura, Vítor Seabra, Rui Medeiros	Pharmacogenomics	2014	6	5	2
10.2217/pgs.14.140	 Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab 	Giacomo Allegrini, Luigi Coltelli, Paola Orlandi, Andrea Fontana, Andrea Camerini, Antonella Ferro, Marina Cazzaniga, Virginia Casadei, Sara Lucchesi, Eleonora Bona, Marco Di Lieto, Ilaria Pazzagli, Federica Villa, Domenico Amoroso, Marco Scalese, Giada Arrighi, Sabrina Molinaro, Anna Fioravanti, Chiara Finale, Renza Triolo, Teresa Di Desidero, Sara Donati, Lorenzo Marcucci, Orlando Goletti, Marzia Del Re, Barbara Salvadori, Ilaria Ferrarini, Romano Danesi, Alfredo Falcone, Guido Bocci	Pharmacogenomics	2014	7	5	5
10.2217/pgs.14.148	Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer	Angelos Koutras, Vasiliki Kotoula, George Fountzilas	Pharmacogenomics	2015	6	5	5
10.2217/pgs.14.150	 COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine 	Marta Bosia, Cristina Lorenzi, Adele Pirovano, Carmelo Guglielmino, Federica Cocchi, Marco Spangaro, Placido Bramanti, Enrico Smeraldi, Roberto Cavallaro	Pharmacogenomics	2015	5	5	3
10.2217/pgs.14.154	Pharmacogenetics of inflammatory bowel disease	Konstantinos H Katsanos, Konstantinos A Papadakis	Pharmacogenomics	2014	5	5	5
10.2217/pgs.14.159	Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells	Xiangning Meng, Geng Wang, Rongwei Guan, Xueyuan Jia, Wei Gao, Jie Wu, Jingcui Yu, Peng Liu, Yang Yu, Wenjing Sun, Haiying Dong, Songbin Fu	Pharmacogenomics	2015	5	5	4
10.2217/pgs.14.162	Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors	David Della-Morte, Raffaele Palmirotta, Ashish K Rehni, Donatella Pastore, Barbara Capuani, Francesca Pacifici, Maria Laura De Marchis, Kunjan R Dave, Alfonso Bellia, Giuseppe Fogliame, Patrizia Ferroni, Giulia Donadel, Francesco Cacciatore, Pasquale Abete, Chuanhui Dong, Antonello Pileggi, Mario Roselli, Camillo Ricordi, Paolo Sbraccia, Fiorella Guadagni, Tatjana Rundek, Davide Lauro	Pharmacogenomics	2014	5	5	5
10.2217/pgs.14.175	FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors	Ariana Montes, Eva Perez-Pampin, Beatriz Joven, Patricia Carreira, Antonio Fernández-Nebro, María del Carmen Ordóñez, Federico Navarro-Sarabia, Virginia Moreira, Yiannis Vasilopoulos, Theologia Sarafidou, Rafael Caliz, Miguel Angel Ferrer, Juan D Cañete, Arturo R de la Serna, Berta Magallares, Javier Narváez, Juan J Gómez-Reino, Antonio Gonzalez	Pharmacogenomics	2015	5	5	3
10.2217/pgs.14.25	Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update	Hong Zhu, Fei-Yan Deng, Xing-Bo Mo, Ying-Hua Qiu, Shu-Feng Lei	Pharmacogenomics	2014	5	5	4
10.2217/pgs.14.26	Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate	Olga G Kulakova, Ekaterina Yu Tsareva, Dmitrijs Lvovs, Alexander V Favorov, Alexey N Boyko, Olga O Favorova	Pharmacogenomics	2014	7	5	3
10.2217/pgs.14.80	Role of solute carrier transporters in pancreatic cancer: a review	Radmila Lemstrová, Pavel Souček, Bohuslav Melichar, Beatrice Mohelnikova-Duchonova	Pharmacogenomics	2014	5	5	5
10.2217/pgs.15.21	Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review	Samantha Jarjour, Mathieu Barrette, Valérie Normand, Jean Lucien Rouleau, Marie-Pierre Dubé, Simon de Denus	Pharmacogenomics	2015	5	5	4
10.2217/pgs.15.70	Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score	Linda M Henricks, Carin ATC Lunenburg, Didier Meulendijks, Hans Gelderblom, Annemieke Cats, Jesse J Swen, Jan HM Schellens, Henk-Jan Guchelaar	Pharmacogenomics	2015	5	5	4
10.2217/pgs.15.83	Genetic markers of recurrence in colorectal cancer	Maria Anna Smolle, Martin Pichler, Johannes Haybaeck, Armin Gerger	Pharmacogenomics	2015	5	5	5
10.2217/pgs.15.87	Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients	Qi Peng, Shujun Huang, Xiaoying Chen, Yayan Yuan, Yajun Yu, Liang Tao, Zhenlu Zhang, Mousheng Xu	Pharmacogenomics	2015	5	5	1
10.2217/pgs.13.173	Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment	Jian-Quan Luo, Lu-Yan Wang, Fa-Zhong He, Ning-Ling Sun, Gen-Fu Tang, Jia-Gen Wen, Zhi-Ying Luo, Zhao-Qian Liu, Hong-Hao Zhou, Xiao-Ping Chen, Wei Zhang	Pharmacogenomics	2014	4	4	2
10.2217/pgs.13.232	Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment	Juan Jose Cerezo-Manchado, Vanessa Roldan, Mario Rosafalco, Ana Isabel Anton, Ana Belen Arroyo, Nuria Garcia-Barbera, Ana Belen Martínez, Jose Padilla, Javier Corral, Vicente Vicente, Rocio Gonzalez-Conejero	Pharmacogenomics	2014	4	4	4
10.2217/pgs.13.237	Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer	Andrey V Khrunin, Denis V Khokhrin, Alexey A Moisseev, Vera A Gorbunova, Svetlana A Limborska	Pharmacogenomics	2014	5	4	3
10.2217/pgs.13.239	ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts	Hidayati Mohd Sha‘ari, Batoul Sadat Haerian, Larry Baum, Junji Saruwatari, Hui Jan Tan, Mohd Hanip Rafia, Azman Ali Raymond, Patrick Kwan, Takateru Ishitsu, Kazuko Nakagawa, Kheng Seang Lim, Zahurin Mohamed	Pharmacogenomics	2014	5	4	2
10.2217/pgs.13.249	TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype	Raffaella Franca, Paola Rebora, Emmanouil Athanasakis, Diego Favretto, Federico Verzegnassi, Giuseppe Basso, Alberto Tommasini, Maria Grazia Valsecchi, Giuliana Decorti, Marco Rabusin	Pharmacogenomics	2014	4	4	2
10.2217/pgs.14.102	Personalized pharmacogenomics profiling using whole-genome sequencing	Clint Mizzi, Brock Peters, Christina Mitropoulou, Konstantinos Mitropoulos, Theodora Katsila, Misha R Agarwal, Ron HN van Schaik, Radoje Drmanac, Joseph Borg, George P Patrinos	Pharmacogenomics	2014	5	4	4
10.2217/pgs.14.119	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study	Francesca Frau, Roberta Zaninello, Erika Salvi, Maria Francesca Ortu, Daniele Braga, Dinesh Velayutham, Giuseppe Argiolas, Giovanni Fresu, Chiara Troffa, Emanuela Bulla, Patrizia Bulla, Silvia Pitzoi, Daniela Antonella Piras, Valeria Glorioso, Martina Chittani, Giampaolo Bernini, Michele Bardini, Francesco Fallo, Lorenzo Malatino, Benedetta Stancanelli, Giuseppe Regolisti, Claudio Ferri, Giovanbattista Desideri, Giuseppe Antonio Scioli, Ferruccio Galletti, Angela Sciacqua, Francesco Perticone, Ezio Degli Esposti, Alessandra Sturani, Andrea Semplicini, Franco Veglio, Paolo Mulatero, Tracy A Williams, Chiara Lanzani, Timo P Hiltunen, Kimmo Kontula, Eric Boerwinkle, Stephen T Turner, Paolo Manunta, Cristina Barlassina, Daniele Cusi, Nicola Glorioso	Pharmacogenomics	2014	6	4	2
10.2217/pgs.14.141	Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole	Manuel Román, Dolores Ochoa, Sergio Daniel Sánchez-Rojas, Maria Talegón, Rocio Prieto-Pérez, Ângela Rivas, Francisco Abad-Santos, Teresa Cabaleiro	Pharmacogenomics	2014	4	4	4
10.2217/pgs.14.156	Genetics and nonmelanoma skin cancer in kidney transplant recipients	Michael T Burke, Nicole Isbel, Katherine A Barraclough, Ji-Won Jung, James W Wells, Christine E Staatz	Pharmacogenomics	2015	4	4	4
10.2217/pgs.14.16	Pharmacogenomics of oral antiplatelet drugs	Alfi Yasmina, Anthonius de Boer, Olaf H Klungel, Vera HM Deneer	Pharmacogenomics	2014	4	4	4
10.2217/pgs.14.177	Evaluation of association studies and meta-analyses of MTHFR gene polymorphisms in colorectal cancer	Batoul Sadat Haerian, Monir Sadat Haerian	Pharmacogenomics	2015	4	4	3
10.2217/pgs.14.179	Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20+ B-cell lymphoma	Annegret Reichwagen, Marita Ziepert, Markus Kreuz, Ute Gödtel-Armbrust, Tanja Rixecker, Viola Poeschel, Mohammad Reza Toliat, Peter Nürnberg, Mladen Tzvetkov, Shiwei Deng, Lorenz Trümper, Gerd Hasenfuss, Michael Pfreundschuh, Leszek Wojnowski	Pharmacogenomics	2015	5	4	3
10.2217/pgs.14.182	Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity	Claudia Lanvers-Kaminsky, Jason A Sprowl, Ingrid Malath, Dirk Deuster, Maria Eveslage, Eberhard Schlatter, Ron HJ Mathijssen, Joachim Boos, Heribert Jürgens, Antionette G am Zehnhoff-Dinnesen, Alex Sparreboom, Giuliano Ciarimboli	Pharmacogenomics	2015	4	4	2
10.2217/pgs.14.186	SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy	Chun-Lai Ma, Xun-Yi Wu, Zheng Jiao, Zhen Hong, Zhi-Yuan Wu, Ming-Kang Zhong	Pharmacogenomics	2015	4	4	2
10.2217/pgs.14.41	Epigenetic perspectives on cancer chemotherapy response	Mou-Ze Liu, Howard L McLeod, Fa-Zhong He, Xiao-Ping Chen, Hong-Hao Zhou, Yan Shu, Wei Zhang	Pharmacogenomics	2014	13	4	2
10.2217/pgs.14.49	Pharmacogenetics of ovarian response	Belen Lledo, Jose A Ortiz, Joaquin Llacer, Rafael Bernabeu	Pharmacogenomics	2014	4	4	4
10.2217/pgs.14.67	Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?	Juliana Salazar, Patricia Moya, Albert Altés, César Díaz-Torné, Jordi Casademont, Dacia Cerdà-Gabaroi, Hèctor Corominas, Montserrat Baiget	Pharmacogenomics	2014	4	4	4
10.2217/pgs.14.69	 HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population 	Fanping Yang, Bo Gu, Lirong Zhang, Jiekun Xuan, Heng Luo, Peng Zhou, Qinyuan Zhu, Sijia Yan, Sheng-an Chen, Zhihao Cao, Jinhua Xu, Qinghe Xing, Xiaoqun Luo	Pharmacogenomics	2014	4	4	3
10.2217/pgs.14.76	Functional role of miRNA in cardiac resynchronization therapy	Celestino Sardu, Raffaele Marfella, Gaetano Santulli, Giuseppe Paolisso	Pharmacogenomics	2014	4	4	4
10.2217/pgs.15.10	Pharmacogenomic assessment of Mexican and Peruvian populations	Sharon Marsh, Cristi R King, Derek J Van Booven, Jane Y Revollo, Robert H Gilman, Howard L McLeod	Pharmacogenomics	2015	4	4	3
10.2217/pgs.15.16	Pharmacogenetic considerations in the treatment of gout	Rebecca L Roberts, Lisa K Stamp	Pharmacogenomics	2015	4	4	3
10.2217/pgs.15.40	Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers	Dolores Ochoa, Rocío Prieto-Pérez, Manuel Román, María Talegón, Angela Rivas, Ignacio Galicia, Francisco Abad-Santos, Teresa Cabaleiro	Pharmacogenomics	2015	4	4	3
10.2217/pgs.15.71	Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus	Maciej Romanowski, Violetta Dziedziejko, Agnieszka Maciejewska-Karlowska, Marek Sawczuk, Krzysztof Safranow, Leszek Domanski, Andrzej Pawlik	Pharmacogenomics	2015	4	4	4
10.2217/pgs.15.89	Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient	Da-Peng Dai, Chuan-Bao Li, Shuang-Hu Wang, Jie Cai, Pei-Wu Geng, Yun-Fang Zhou, Guo-Xin Hu, Jian-Ping Cai	Pharmacogenomics	2015	4	4	2
10.2217/pgs.15.93	Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability	Jacob T Brown, Jeffrey R Bishop	Pharmacogenomics	2015	5	4	4
10.2217/pgs.13.199	CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients	Mateusz Kurzawski, Justyna Dąbrowska, Krzysztof Dziewanowski, Leszek Domański, Magdalena Perużyńska, Marek Droździk	Pharmacogenomics	2014	3	3	3
10.2217/pgs.13.203	CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico	Blanca Patricia Lazalde-Ramos, Margarita de la Luz Martínez-Fierro, Carlos Galaviz-Hernández, Idalia Garza-Veloz, María Eugenia G Naranjo, Martha Sosa-Macías, Adrián LLerena	Pharmacogenomics	2014	4	3	3
10.2217/pgs.13.204	Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial	Patricia Gassó, Sergi Mas, Katerina Papagianni, Eva Ferrando, Ramón Fernández de Bobadilla, Joan Albert Arnaiz, Miquel Bioque, Miquel Bernardo, Amalia Lafuente	Pharmacogenomics	2014	4	3	3
10.2217/pgs.13.222	MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis	Bailing Zu, Yajuan Li, Xin Wang, Dali He, Zhenglan Huang, Wenli Feng	Pharmacogenomics	2014	3	3	2
10.2217/pgs.13.223	Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism	Natascha Schweighofer, Elisabeth Lerchbaum, Olivia Trummer, Verena Schwetz, Thomas Pieber, Barbara Obermayer-Pietsch	Pharmacogenomics	2014	3	3	3
10.2217/pgs.13.234	Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes	Jazlina Liza Jamaluddin, Hasniza Zaman Huri, Shireene Ratna Vethakkan, Norlaila Mustafa	Pharmacogenomics	2014	4	3	2
10.2217/pgs.14.136	 Impact of VEGF gene polymorphisms in elderly cancer patients: clinical outcome and toxicity 	David Della-Morte, Silvia Riondino, Patrizia Ferroni, Raffaele Palmirotta, Donatella Pastore, Davide Lauro, Fiorella Guadagni, Mario Roselli	Pharmacogenomics	2015	3	3	3
10.2217/pgs.14.142	Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy	Xu Zhu, Wenting Yun, Xiaofu Sun, Feng Qiu, Limei Zhao, Yingjie Guo	Pharmacogenomics	2014	3	3	2
10.2217/pgs.14.149	Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands	Talitha I Verhoef, William K Redekop, Anthonius de Boer, Anke Hilse Maitland-van der Zee, None None	Pharmacogenomics	2015	3	3	2
10.2217/pgs.14.21	An update on the pharmacogenomics of metformin: progress, problems and potential	Jennifer N Todd, Jose C Florez	Pharmacogenomics	2014	4	3	2
10.2217/pgs.14.50	Pharmacogenetics of second-generation antipsychotics	Mark D Brennan	Pharmacogenomics	2014	3	3	3
10.2217/pgs.14.62	Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins	Aizati NA Daud, Jorieke EH Bergman, Marian K Bakker, Hao Wang, Hermien EK de Walle, Torsten Plösch, Bob Wilffert	Pharmacogenomics	2014	4	3	3
10.2217/pgs.14.68	Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia	Francesco Ceppi, Chloé Langlois-Pelletier, Vincent Gagné, Julie Rousseau, Claire Ciolino, Samanta De Lorenzo, Kojok M Kevin, Diana Cijov, Stephen E Sallan, Lewis B Silverman, Donna Neuberg, Jeffery L Kutok, Daniel Sinnett, Caroline Laverdière, Maja Krajinovic	Pharmacogenomics	2014	3	3	3
10.2217/pgs.14.81	Development of a broad-based ADME panel for use in pharmacogenomic studies	Andrew MK Brown, Yannick Renaud, Colin Ross, Mark Hansen, Ian Mongrain, Diane Valois, Bruce C Carleton, Michael R Hayden, Marie-Pierre Dubé, Jean-Claude Tardif, Michael S Phillips	Pharmacogenomics	2014	3	3	3
10.2217/pgs.14.83	Pharmacogenetics of antidepressant treatment in obsessive–compulsive disorder: an update and implications for clinicians	Gwyneth Zai, Eva J Brandl, Daniel J Müller, Margaret A Richter, James L Kennedy	Pharmacogenomics	2014	3	3	3
10.2217/pgs.14.88	Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population	Anil K Giri, Nazir M Khan, Sandeep Grover, Ismeet Kaur, Analabha Basu, Nikhil Tandon, Vinod Scaria, IGV Consortium, Ritushree Kukreti, Samir K Brahmachari, Dwaipayan Bharadwaj	Pharmacogenomics	2014	5	3	2
10.2217/pgs.15.23	Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?	Mariana Rieck, Artur F Schumacher-Schuh, Sidia M Callegari-Jacques, Vivian Altmann, Márcio Schneider Medeiros, Carlos RM Rieder, Mara H Hutz	Pharmacogenomics	2015	3	3	2
10.2217/pgs.15.24	Interethnic relationships of CYP2D6 variants in native and Mestizo populations sharing the same ecosystem	Yadira Xitlalli Perez-Paramo, Francisco Hernandez-Cabrera, Pedro Dorado, Adrian Llerena, Sergio Muñoz-Jimenez, Rocio Ortiz-Lopez, Augusto Rojas-Martinez	Pharmacogenomics	2015	3	3	2
10.2217/pgs.15.26	Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients	Xi Li, Rong Liu, Zhi-Ying Luo, Han Yan, Wei-Hua Huang, Ji-Ye Yin, Xiao-Yuan Mao, Xiao-Ping Chen, Zhao-Qian Liu, Hong-Hao Zhou, Wei Zhang	Pharmacogenomics	2015	6	3	1
10.2217/pgs.15.3	Biomarkers of hippocampal gene expression in a mouse restraint chronic stress model	Massimo Ubaldi, Eugenia Ricciardelli, Lorenza Pasqualini, Giuseppina Sannino, Laura Soverchia, Barbara Ruggeri, Silvia Falcinelli, Alessandra Renzi, Colleen Ludka, Roberto Ciccocioppo, Gary Hardiman	Pharmacogenomics	2015	4	3	3
10.2217/pgs.15.31	CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study	Kristina Probst-Schendzielorz, Catharina Scholl, Olga Efimkina, Eva Ersfeld, Roberto Viviani, Alessandro Serretti, Chiara Fabbri, David Gurwitz, Susanne Lucae, Marcus Ising, Anna Maria Paul, Marie-Louise Lehmann, Michael Steffens, Concetta Crisafulli, Marco Calabrò, Florian Holsboer, Julia Stingl	Pharmacogenomics	2015	4	3	3
10.2217/pgs.15.39	Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation	Ignacio Sánchez-Lázaro, María José Herrero, Consuelo Jordán-De Luna, Virginia Bosó, Luis Almenar, Luis Rojas, Luis Martínez-Dolz, Juan E Megías-Vericat, Luis Sendra, Antonio Miguel, José L Poveda, Salvador F Aliño	Pharmacogenomics	2015	3	3	3
10.2217/pgs.15.53	Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry	Ana Alfirevic, Jill Durocher, Anisa Elati, Wilfrido León, David Dickens, Steffen Rädisch, Helen Box, Marco Siccardi, Paul Curley, George Xinarianos, Arjun Ardeshana, Andrew Owen, J Eunice Zhang, Munir Pirmohamed, Zarko Alfirevic, Andrew Weeks, Beverly Winikoff	Pharmacogenomics	2015	3	3	2
10.2217/pgs.15.56	BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients	Romain Colle, Eric Deflesselle, Séverine Martin, Denis J David, Patrick Hardy, Adéla Taranu, Bruno Falissard, Céline Verstuyft, Emmanuelle Corruble	Pharmacogenomics	2015	3	3	3
10.2217/pgs.15.73	Genome-wide association study of warfarin maintenance dose in a Brazilian sample	Esteban J Parra, Mariana R Botton, Jamila A Perini, S Krithika, Stephane Bourgeois, Todd A Johnson, Tatsuhiko Tsunoda, Munir Pirmohamed, Mia Wadelius, Nita A Limdi, Larisa H Cavallari, James K Burmester, Allan E Rettie, Teri E Klein, Julie A Johnson, Mara H Hutz, Guilherme Suarez-Kurtz	Pharmacogenomics	2015	4	3	3
10.2217/pgs.15.81	Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity	Dominic Kummer, Tanja K Froehlich, Markus Joerger, Stefan Aebi, Johanna Sistonen, Ursula Amstutz, Carlo R Largiadèr	Pharmacogenomics	2015	3	3	3
10.2217/pgs.13.186	Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM study	Raffaele Palmirotta, Piero Barbanti, Giorgia Ludovici, Maria Laura De Marchis, Cristiano Ialongo, Gabriella Egeo, Cinzia Aurilia, Luisa Fofi, Pasquale Abete, Antonella Spila, Patrizia Ferroni, David Della-Morte, Fiorella Guadagni	Pharmacogenomics	2014	2	2	1
10.2217/pgs.13.226	Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes	Alice Matimba, Fang Li, Alina Livshits, Cher S Cartwright, Stephen Scully, Brooke L Fridley, Gregory Jenkins, Anthony Batzler, Liewei Wang, Richard Weinshilboum, Lynne Lennard	Pharmacogenomics	2014	2	2	2
